Report & Accounts

Overview

The report covers Avacta's 17-month transition to a 31 December year-end, with Group revenue of £5.51 million. It highlights progress in the pre|CISION and Affimer platforms, including AVA6000 and the first Affimer clinical candidate, alongside therapeutic partnerships. Post-period, the company formed COVID-19 diagnostic collaborations with Cytiva and Adeptrix.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2019
Period: Ends 31 December 2019
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services